Visible Tumor Uptake and Recommended Dose Increase in Spago Nanomedicals's Phase I/IIa Study Tumorad-01
Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends a dose increase in the ongoing Phase I/IIa clinical trial Tumorad-01 with the radiopharmaceutical drug candidate 177Lu-SN201. In addition, significant visible tumor uptake of 177Lu-SN201 has been observed on SPECT images, which can be considered a proof-of-concept for Tumorad in humans according to the DMC. This...
Read more









